SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis
Diabetology International · 2026-10 · 17 (4)
DOI: 10.1007/s13340-026-00934-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetology International, online erschienen am 05.10.2026. Verfasst von Arif Saleem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Hypertension Hospital, Khyber Medical University, Dera Ismail Khan, Pakistan. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
This study evaluates the efficacy of combination therapy with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) versus DPP-4i monotherapy in patients with type 2 diabetes mellitus (T2DM) who remained inadequately controlled on metformin.
Methods
Randomized controlled trials (RCTs) investigating adults with T2DM inadequately controlled on metformin, comparing the combination of SGLT-2i plus DPP-4i versus DPP-4i add-on therapy alone were systematically reviewed. PubMed/Medline, Google Scholar, Embase, and CENTRAL were searched without language restriction. The primary outcomes were change in HbA1c and in fasting plasma glucose (FPG) from baseline, proportion of patients attainting HbA1c < 7.0%, and body weight reduction. Secondary outcomes included hypoglycemia risk, genital infection, urinary tract infection (UTI), and overall and serious adverse events (AEs). Pooled analyses were carried out using the random-effects model.
Results
Eleven RCTs (3662 patients) were pooled. Compared with DPP-4i alone, adding a combination of SGLT-2i plus DPP-4i after metformin significantly reduced HbA1c (MD: - 0.47%; 95% CI (- 0.54, - 0.41); GRADE: high), increased the proportion of patients attaining HbA1c < 7.0% (RR: 1.71; 95% CI (1.52, 1.93); GRADE: moderate), reduced FPG (MD: - 15.75 mg/dL; 95% CI (- 21.56, - 9.93); GRADE: moderate), increased genital infection (RR: 2.83 (95% CI 1.02, 7.87; GRADE = moderate), and produced greater body weight reduction (MD: - 1.46 kg; 95% CI (- 1.93, - 0.99); GRADE: moderate). The risk of UTI and overall and serious AEs were insignificantly different between arms.
Conclusion
The combinatorial therapy using SGLT-2i and DPP-4i produces a significantly better glycemic control and body weight compared with DPP-4i therapy alone, without increasing the overall safety burden. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13340-026-00934-1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetes and Hypertension Hospital, Khyber Medical University, Dera Ismail Khan, Pakistan.
- Khyber Medical College, Peshawar, Pakistan.
- Institute of Radiotherapy and Nuclear Medicine, Peshawar, Pakistan.
ORCID-Profile: Iftikhar Ahmad
Zitieren
APA
Saleem, A., Shinwari, H., Usman, M., Adil, K., Khan, A., Shah, H., & Ahmad, I. (2026). SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis. Diabetology International, 17(4). https://doi.org/10.1007/s13340-026-00934-1
Vancouver
Saleem A, Shinwari H, Usman M, Adil K, Khan A, Shah H, et al. SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis. Diabetology International. 2026;17(4). doi:10.1007/s13340-026-00934-1
BibTeX
@article{Saleem2026,
author = {Saleem, Arif and Shinwari, Haris and Usman, Muhammad and Adil, Kamran and Khan, Asfandyar and Shah, Humam and Ahmad, Iftikhar},
title = {SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis},
journal = {Diabetology International},
year = {2026},
volume = {17},
number = {4},
doi = {10.1007/s13340-026-00934-1}
}
EUVIMED